Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

NCT03368859 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03368859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03368859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
March 20, 2018
Completion date
December 18, 2019
Enrollment
70 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

cancer